RCE Insider Trading (Recce Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$50,003.25
Insider Selling (Last 12 Months): A$178,325.00
Recce Pharmaceuticals Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/12/2020 01:00 AM ET
Invest in Artificial Intelligence Before It Changes the World
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive. This is the golden age of investing in artificial intelligence!
Invest in this red-hot industry at pre-IPO prices.
Recce Pharmaceuticals Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
High Arch Potential Stock
If you're looking for a hot new sector, watch this stock closely.
Click for ticker & full details
SEC Filings (Institutional Ownership Changes) for Recce Pharmaceuticals (ASX:RCE)
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti-infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Recce Pharmaceuticals?